Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxycodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxycodone SCHEMBL3121359 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL12945207 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL12960967 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL618773 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL14394071 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL8386507 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL18410410 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22058352 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22163723 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL16015666 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529340-B2 | Combination for treating pain | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-09-17 | — | — | US | disclosed |
| US-10760090-B2 | Papaver somniferum strain with high concentration of thebaine | TASMANIAN ALKALOIDS PTY. LTD. (AU) | 2020-09-01 | — | — | US | disclosed |
| US-10227354-B2 | Conversion of oxycodone base to oxycodone hydrochloride | CODY LABORATORIES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-9909137-B2 | Papaver somniferum strain with high concentration of thebaine | TASMANIAN ALKALOIDS PTY. LTD. (AU) | 2018-03-06 | — | — | US | disclosed |
| US-9776971-B2 | Opioid and opioid-like compounds and uses thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2017-10-03 | — | — | US | disclosed |
| WO-2017165558-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-2010539-B1 | STEREOSELECTIVE REDUCTION OF A MORPHINONE | NEKTAR THERAPEUTICS (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9309257-B2 | Preparation of oxycodone base form 14-hydroxycodeinone sulfate | CODY LABORATORIES, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20160032308-A1 | Papaver Somniferum Strain with High Concentration of Thebaine | TASMANIAN ALKALOIDS PTY LTD (AU) | 2016-02-04 | — | — | US | disclosed |
| US-7875719-B2 | Oxidizing thebaine to produce 14-hydroxycodeinone, hydrogenating to produce oxycodone, mixing with n-butanol, basification with sodium hydroxide, isolating purified oxycodone | NORAMCO, LLC (FORMERLY KNOWN AS NORAMCO, INC.) | 2011-01-25 | — | — | US | disclosed |
| US-20100284960-A1 | Dosage Forms and Co-Administration of Opioid Agonist and Opioid Antagonist | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20090239892-A1 | PYRIDOMORPHINANS, PYRIDAZINOMORPHINANS AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2009-09-24 | — | — | US | disclosed |
| US-7541364-B2 | Pyridomorphinans, pyridazinomorphinans and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2009-06-02 | — | — | US | disclosed |
| US-20090005563-A1 | CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES | BROCK UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
| US-20090005563-A1 | CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES | BROCK UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
| US-20080194568-A1 | Pyridomorphinans, Pyridazinomorphinans and Use Thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080132703-A1 | Oxidizing thebaine to produce 14-hydroxycodeinone, hydrogenating to produce oxycodone, mixing with n-butanol, basification with sodium hydroxide, isolating purified oxycodone | NORAMCO, LLC (FORMERLY KNOWN AS NORAMCO, INC.) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227354-B2 | Conversion of oxycodone base to oxycodone hydrochloride | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | OPRM1 4/4885OPRD1 6/4885OPRK1 3/4885 |
| US-10760090-B2 | Papaver somniferum strain with high concentration of thebaine | OPRM1, POF1B, OPRK1 | OPRM1 1/4885OPRD1 16/4885OPRK1 3/4885 |
| US-20090005563-A1 | CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20100284960-A1 | Dosage Forms and Co-Administration of Opioid Agonist and Opioid Antagonist | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20080194568-A1 | Pyridomorphinans, Pyridazinomorphinans and Use Thereof | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 1/4885 |
| US-20090239892-A1 | PYRIDOMORPHINANS, PYRIDAZINOMORPHINANS AND USE THEREOF | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20080132703-A1 | Oxidizing thebaine to produce 14-hydroxycodeinone, hydrogenating to produce oxycodone, mixing with n-butanol, basification with sodium hydroxide, isolating purified oxycodone | CYP11B1, CYP11B2, DBH | OPRM1 31/4885OPRD1 5/4885OPRK1 25/4885 |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | OPRL1, ACHE, OPRK1 | OPRM1 12/4885OPRD1 6/4885OPRK1 3/4885 |
| US-20160032308-A1 | Papaver Somniferum Strain with High Concentration of Thebaine | OPRM1, POF1B, OPRK1 | OPRM1 1/4885OPRD1 16/4885OPRK1 3/4885 |
| US-11529340-B2 | Combination for treating pain | OPRL1, ACHE, OPRK1 | OPRM1 12/4885OPRD1 6/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.